Please ensure Javascript is enabled for purposes of website accessibility

Got $1,000? These 2 Bargain-Bin Biopharma Stocks Might Be Worth Buying

By Alex Carchidi – Updated Aug 27, 2021 at 4:54PM

Key Points

  • Attractive valuations can be just as important as competitive advantages when it comes to rewarding investors.
  • Low-growth stocks aren't always a bad choice.
  • Here are two investments to put on your watch list and consider picking up.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These healthcare stocks have their warts, but the price is right for long-term investors.

If you've ever bought a cheap gadget of questionable durability because the price was too good to pass up, you know that bargains come in all shapes and sizes. Sometimes, buying undervalued stocks can be a good decision. Old-school value investors like Benjamin Graham were often willing to buy stocks in companies that many perceived to be of dubious quality as long as they saw some potential and they were priced appropriately. 

While it's typically hard to find bargains in the biopharma sector, they do exist. Both of the companies I'll discuss today are profitable, they have several products on the market to supply steady revenue -- and they might be undervalued.

But to figure out whether they are worth buying, you'll need to understand their valuation as well as their chances of breaking out from their current doldrums. So let's dive in. 

A scientist works at a lab bench while two other scientists look on.

Image source: Getty Images.

An under-the-radar pharma value play

Antares Pharma (ATRS) sells a small handful of drugs for arthritis, migraine, and testosterone therapy. Many of its products are administered via the company's proprietary auto-injector devices, which it also deploys to sell certain generic drugs with the help of its commercial partners. Per the second-quarter report, things are going swimmingly: Quarterly revenue increased by 38.9% and quarterly earnings grew by 103.2% compared to the same period in 2020. 

So why is this stock's trailing price-to-earnings ratio lingering around 12 when the pharma industry's average is around 56? Why aren't investors stumbling over themselves to buy shares?

It probably has something to do with how Antares has very few wholly owned projects in its development pipeline. Of the projects it's pursuing without collaborators taking the lead, only its hydrocortisone therapy is currently in clinical trials. Given that hydrocortisone is a cheap and ubiquitous generic drug, it's hard to see how Antares could keep growing its revenue by putting it into an auto-injector format. 

Still, the company has survived so far by combining sparse in-house development with sales generated from outside partnerships and licensing. Management plans to keep pushing forward with this mixed strategy. But investors won't have any clue about new partnerships or pipeline projects until Antares announces them, and right now there isn't much on the board. 

In sum, this could easily be a great value stock to own, assuming you're comfortable with investing in a pharma business whose prospects depend mostly on the future deals that management makes.

An undervalued diagnostics stock 

Meridian Bioscience (VIVO -0.19%) makes a handful of diagnostic tests for everything from bacterial infections to parasites, viral illnesses, and even lead poisoning. Its P/E ratio is a scant 12, suggesting that the market is somewhat pessimistic about Meridian's future growth. Part of the reason may be that its earnings and revenue have both been contracting. Compared to a year ago, net revenue dropped by 25% and net earnings crashed 60%, as of the latest quarter ended June 30. 

For growth prospects, Meridian's product pipeline is a bit thin. The only diagnostic it currently has in clinical testing is for detecting a bacteria called C. difficile, which causes an inflammation of the colon, but development is currently stalled, perhaps until next year. While it could have a COVID-19 diagnostic test approved by regulators by year-end, it's hard to imagine the company grabbing a significant share of a crowded market that's populated by a fair number of giant competitors.

Based on the likelihood of its future slow growth, how could this stock be a buy? It boils down to valuation. When paired with its low P/E ratio, the stock looks like a bargain. People who buy it now could see their shares appreciate in value if it reverts toward the market's average. And if its coronavirus test ends up generating significant revenue, the company could reverse its fortunes throughout 2022.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Antares Pharma Stock Quote
Antares Pharma
ATRS
Meridian Bioscience Stock Quote
Meridian Bioscience
VIVO
$31.92 (-0.19%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.